During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating zanubrutinib in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The discussion was chaired by Jacob Soumerai and featured Gilles Salles, Ulrich Jäger, Sonali Smith, Martin Dreyling, Astrid Pavlovsky, Michael Dickinson, and Jennifer Crombie.

Soumerai presented an overview of the SEQUOIA trial, efficacy and safety data, and key takeaways.

This educational resource is independently supported by BeOne Medicines. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

This educational resource is independently supported by Caribou Biosciences. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

During the 31st European Hematology Association (EHA) Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Dr. Talha Munir, Leeds Teaching Hospital, Leeds, UK. We asked, What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in chronic lymphocytic leukemia (CLL)?

This educational resource is independently supported by Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence

Hosted on Acast. See acast.com/privacy for more information.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Brody discussed the key highlights in lymphoma and chronic lymphocytic leukemia (CLL) from the meeting.

Brody highlights several presentations on approved and novel immunotherapies for patients with lymphoma and CLL. He discusses the significant progress made in the treatment of B-cell non-Hodgkin lymphoma (NHL). He also discusses the historically poor outcomes in patients with T-cell lymphoma and highlights some of the novel therapies presented at ASH for this patient population.

Hosted on Acast. See acast.com/privacy for more information.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Alexey Danilov, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)?

This educational resource is independently supported by Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with chronic lymphocytic leukemia (CLL)?

This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What do the primary results from the EPCORE FL-1 trial tell us about epcoritamab + R2 vs R2 alone in patients with R/R FL?

In this interview, Falchi highlights that epcoritamab and R2 do not have overlapping toxicities and that the combination may offer synergistic activity. He concludes that epcoritamab sets a new benchmark as a readily available treatment for patients with R/R FL.

This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.